About THOR Photomedicine
On Star Trek when someone is injured, they are taken to sick bay where the doctor uses a laser to heal the patient instantly. We make those (just not quite as instant).
The treatment is called Photobiomodulation (PBM Therapy) previously known as Low Level Laser Therapy (LLLT) and is considered by many scientists to be "a new branch of medicine" (Dr Roberta Chow MD PhD).
Light (within certain parameters) can regenerate tissue, reduce inflammation and reduce pain. It does this by increasing cellular energy and reducing oxidative stress. These effects have been tested in over 700 clinical trials (RCT's) and thousands of laboratory studies and published in many leading journals including The Lancet, BMJ, Nature, PNAS, Spine, Muscle and Nerve, Pain, Stroke etc.
Dedicated private PBM clinics are being born every month to meet public demand for pain relief and the former head of tissue viability for Scotland Lydia Jack demonstrated that the laser paid for itself with the first patient she treated.
Already THOR has over 5,000 customers in pioneering clinics and hospitals in more than 70 countries and is the only company with FDA, CE, TGA and NATO clearance, and we are also listed on GSA, and eCAT in the United States for government purchases.
Photobiomodulation (PBM) in every department of every hospital.
To heal and relieve pain.
Our decisions and actions must work for all stakeholders;
- Customers & patients
- Employees and their families
- Our community and the rest of humankind
- Professional, honest and fair in all our dealings
To establish Photobiomodulation as a standard of care for
10 diseases in
10 countries in
10 years (end of 2030)
THOR Photomedicine Ltd is privately owned by founder and CEO James Carroll
James Carroll LinkedIn Profile
James Carroll papers
THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.
The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.
The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.
Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.